We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bilirubin Improves Risk Prediction of Cardiovascular Death

By LabMedica International staff writers
Posted on 07 Jan 2019
Diabetes is one of the most prevalent disorders worldwide and cardiovascular (CV) disease is the leading cause of mortality and morbidity in diabetic patients. More...
Therefore, improvements in risk prevention and adequate treatment are needed in these high-risk subjects.

Previous studies have shown that elevated serum bilirubin concentrations might protect against atherosclerosis, yet it remains unclear whether higher serum bilirubin concentrations work in favor of the cardiovascular system in patients with type 2 diabetes.

A team of scientists led by those at the National Yang-Ming University (Taipei, Taiwan, ROC) enrolled 2,936 subjects with type 2 diabetes (1,009 males and 1,927 females; mean age of 62.7 ± 11 years). The goal of the study was to investigate the association between serum bilirubin and subsequent development of cardiovascular death among asymptomatic diabetic patients.

Blood samples were obtained from all patients after an overnight fast of more than 12 hours. Total bilirubin was measured using a Hitachi 7600 chemistry analyzer with a vanadate oxidation method. Lipid profiles including triglycerides, total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) cholesterol, serum total bilirubin, albumin, creatinine, aspartate transaminase (AST), alanine transaminase (ALT, and glucose were also measured at the same time.

The team followed the patients for 5.4 ± 3.0 years, and there were 218 deaths including 95 cardiovascular deaths. The occurrence of CV death and all-cause death were negatively correlated with increasing serum bilirubin quintiles and actual bilirubin values. Serum bilirubin was negatively associated with incident cardiovascular death and all-cause death. The addition of bilirubin for cardiovascular death increased the C-statistic from 0.713 to 0.729 and showed an integrated discrimination improvement (IDI) of 0.012 with 8.57% improvement in net reclassification analysis.

The authors concluded that higher serum concentrations of bilirubin are associated with a decreased risk of developing CV and all-cause death in diabetic patients. Bilirubin improved the risk prediction of cardiovascular death but provided only a slightly better prediction of all-cause death than conventional risk factors. The study was published in the January 2019 issue of the journal Clinica Chimica Acta.

Related Links:
National Yang-Ming University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Drug Testing Assays
Atellica DT 250 Analyzer
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.